ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Relationship Between Glucose/Lipid Metabolism and Placental Biomarkers in Gestational Diabetes and Preeclampsia.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prenatal prediction of neonatal respiratory distress syndrome using uteroplacental Doppler and placental microvascular perfusion indices: development of a risk model.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the significance and relationship of glucose and lipid metabolism, placental resistin, and human lipid carrier protein (LCN-2) expression in pregnant women with gestational diabetes mellitus (GDM) complicated by severe preeclampsia (SPE). Methods: A total of 89 patients with GDM and SPE (G+S group) and 89 patients with GDM alone (GDM group) were included. Blood samples were collected to measure glucose and lipid metabolism indicators [fasting blood glucose (FBG), fasting insulin (FINS), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), HDL-C, and LDL-C], and immunohistochemistry was used to assess placental resistin and LCN-2 levels. Delivery conditions and adverse maternal and neonatal outcomes were compared. Pearson correlation analysis was conducted to explore the relationship between placental resistin, LCN-2, and glucose and lipid metabolism indicators. Results: FBG, FINS, HbA1c, TC, and TG levels were higher, and HDL-C was lower in the G+S group compared to the GDM group (P<0.05). The positive expression rates of resistin and LCN-2 in placental tissue were also higher in the G+S group (P<0.05). The G+S group had lower gestational weeks, neonatal birth weight, and higher postpartum hemorrhage than the GDM group (P<0.05). The G+S group showed higher rates of adverse maternal outcomes (postpartum hemorrhage, intrauterine infection) and neonatal outcomes (preterm birth, fetal distress) (P<0.05). Pearson analysis showed that placental resistin and LCN-2 expression were positively correlated with FBG, FINS, TC, and TG, and negatively correlated with HDL-C (P<0.05). Conclusion: Pregnant women with GDM and SPE have higher risks of glucose and lipid metabolism disorders, placental resistin and LCN-2 expression, and adverse maternal and neonatal outcomes compared to GDM patients. Resistin and LCN-2 may influence glucose and lipid metabolism, affecting pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.